Latest by Barbara Jungwirth

This Week in HIV Research: A Long-Acting Popularity Contest

The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: This Is Your Brain on Stigma

The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Let's Get Real About Treatment Efficacy

Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

By Barbara Jungwirth and Myles Helfand

Loneliness, Depression, Financial Problems, and Comorbidities Top List of Issues Faced by Older Adults Living With HIV in New Report

Comorbidities, mental health issues, loneliness, and financial problems are the biggest issues faced by older people living with HIV, the San Francisco portion of a new report issued by the ACRIA Center on HIV and Aging at GMHC showed.

By Barbara Jungwirth

This Week in HIV Research: Getting Smart(Phone) About HIV Detection

A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Many Black MSM on PrEP Are Already Positive

High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.

By Barbara Jungwirth and Myles Helfand

Dapivirine Vaginal Ring for PrEP Does Not Lead to Drug Resistance

Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.

By Barbara Jungwirth

This Week in HIV Research: How Should We Measure Success?

The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The PrEP Sex/Race Gap

PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.

By Barbara Jungwirth and Myles Helfand